Eris લાઇફસાયન્સ શેર કિંમત

ફાર્માસ્યુટિકલ કંપનીએ ઘરેલું ફોર્મ્યુલેશન અને ઇન્સુલિન ફ્રેન્ચાઇઝી પરફોર્મન્સમાં મજબૂત વૃદ્ધિ નોંધાવી છે, જ્યારે 37 ટકાનું મજબૂત EBITDA માર્જિન જાળવી રાખ્યું છે

• બિઝનેસ સ્ટાન્ડર્ડ
• 1 અઠવાડિયા 5 દિવસ પહેલાં

Pharmaceuticals company Eris Lifesciences announced Q4FY26 & FY26 results Consolidated Financial Highlights: Total Revenue from Operations: Q4FY26: Rs 756.56 crore compared to Rs 705.30 crore in Q4FY25 (YoY growth of ~7.3%). FY26: Rs 3,129.42 crore compared to Rs 2,893.64 crore in FY25 (YoY growth of ~8.1%). Net Profit for the period: Q4FY26: Rs 279.10 crore compared to Rs 102.35 crore in Q4FY25 (YoY growth of ~172.7%). FY26: Rs 647.51 crore compared to Rs 374.67 crore in FY25 (YoY growth of ~72.8%). Standalone Financial Highlights: Total Revenue from Operations: Q4FY26: Rs 277.31 crore compared to Rs 404.77 crore in Q4FY25 (YoY decline of ~31.5%). FY26: Rs 1,821.74 crore compared to Rs 1,697.75 crore in FY25 (YoY growth of ~7.3%). Net Profit for the period: Q4FY26: Net loss of Rs 8.60 crore compared to profit of Rs 30.47 crore in Q4FY25. FY26: Rs 244.05 crore compared to Rs 77.39 crore in FY25 (YoY growth of ~215.3%). Business Highlights: Dividend Declaration: The Board declared an interim dividend of Rs 7.21 per fully paid-up equity share (at the rate of 721%) for the financial year 2026-2027. The record date is May 29, 2026, and payment will be made on or before June 19, 2026. Acquisitions: Swiss Parenteral Limited (SPL): Completed the acquisition of the remaining minority shares on January 16, 2026, making it a wholly-owned subsidiary. Branded Probiotics Business: Completed the acquisition from Velbiom Probiotics Private Limited on March 31, 2026, for a consideration of Rs 50 crore on a slump sale basis. Regulatory/Tax Impact: Due to eligibility for the concessional tax regime from the financial year 2026-27, the Company remeasured deferred tax assets and liabilities, resulting in a deferred tax credit of Rs 150 crore (consolidated) and Rs 18 crore (standalone) recognized in the Statement of Profit and Loss. Exceptional Items: The Company recorded an exceptional item charge of Rs 17.24 crore (consolidated) and Rs 14.67 crore (standalone) in FY26 related to an increase in gratuity and leave liability due to the implementation of the New Labour Codes. Scheme of Arrangement: The Board approved a composite scheme of arrangement to vest the "Domestic Business" of Eris Oaknet Healthcare Private Limited (EOHPL) into Eris Therapeutics Limited (ETL) and the amalgamation of Aprica Healthcare Limited (AHL) with ETL. This is subject to necessary statutory approvals. Result PDF

• ટ્રેન્ડલાઇન
• 1 અઠવાડિયા 5 દિવસ પહેલાં

ફાર્માસ્યુટિકલ્સ કંપની એરિસ લાઇફસાયન્સે Q3FY26 કામગીરીમાંથી આવકની જાહેરાત કરી: Q3FY25 દરમિયાન ₹ 727.45 કરોડ સામે ₹ 807.45 કરોડ, ફેરફાર 11%. પીબીટી: Q3FY25 દરમિયાન ₹ 116.36 કરોડ સામે ₹ 145.35 કરોડ, 25% બદલો. પીએટી: Q3FY25 દરમિયાન ₹87.06 કરોડ સામે ₹108.83 કરોડ, 25% બદલો. ઇપીએસ: Q3FY26 માટે ₹ 7.32. Q3 કેપેક્સ ₹ 78 કરોડ - મોટાભાગે ઇન્સુલિન/GLP-1 અને જનરલ ઇન્જેક્ટેબલ બુક ટૅક્સ રેટ - Q3 OCF-to-EBIDTA રેશિયોમાં 22.5%: Q3-26 માં 50% વર્સેસ Q3-25 પરિણામ PDF માં 120%

• ટ્રેન્ડલાઇન
• 3 મહિના 2 અઠવાડિયા પહેલાં